# A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Source: https://onco.cc/trials/nct02747004/  
OnCo record `nct02747004` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abemaciclib and Tamoxifen in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer is a phase 2 interventional study registered as NCT02747004 by Eli Lilly and Company, with 234 participants enrolled, started 2016-09-14 and due to reach its primary completion in 2018-06-15. Interventions recorded: Abemaciclib, Tamoxifen and Prophylactic Loperamide. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: Next MONARCH 1
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02747004
- Phase: 2
- Setting: A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 234
- Outcomes: Progression Free Survival (PFS): 150mg Abemaciclib + 20mg Tamoxifen 9.07 months vs 150mg Abemaciclib 6.48 months vs 200mg Abemaciclib + 2mg Prophylactic Loperamide 7.43 months; Objective Response Rate (ORR): Percentage of Participants With a Complete Response (CR) or Partial Response (PR): 150mg Abemaciclib + 20mg Tamoxifen 34.6% vs 150mg Abemaciclib 24.1% vs 200mg Abemaciclib + 2mg Prophylactic Loperamide 32.5%

## Sources

- ClinicalTrials.gov NCT02747004: https://clinicaltrials.gov/study/NCT02747004

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct02747004.json